Sigma has handed in its half year results…
The post Sigma (ASX:SIG) share price sinks 7% on half year update and guidance downgrade appeared first on The Motley Fool Australia. –
In early trade, the pharmacy chain operator and distributor’s shares dropped as much as 7% to 58.5 cents.
The Sigma share price has recovered a touch since then and is now down 3% to 61 cents.
Sigma share price tumbles on guidance downgrade
Revenue up 5.5% to $1.73 billion
Like for like pharmacy sales up 8.7%
Underlying EBITDA up 14.7% to $39.2 million
Underlying net profit after tax up 23.7% to $14.1 million
Fully franked interim dividend of 1 cent per share
Net debt of $82 million
Outlook: FY 2022 underlying EBITDA guidance now 5% (from ~10% previously)
What happened during the first half?
For the six months ended 31 July, Sigma reported a 5.5% increase in revenue to $1.73 billion. Management advised that this was driven by a combination of above market organic growth across its pharmacy brands and independent network, a full run rate of sales to Chemist Warehouse, and the incremental on-boarding of a number of new customers.
PBS sales were up 14% for the half, with over the counter sales up 32%. However, excluding Chemist Warehouse, over the counter sales were down 5.4%. This reflects general market conditions including the softer cold and flu category.
On the bottom line, the company’s underlying net profit after tax increased 23.7% to $14.1 million. Management advised that this reflects its positive sales performance and operational platform efficiency.
What did management say?
Sigma’s CEO and Managing Director, Mark Hooper, was pleased with the half.
He commented: “It is pleasing to navigate a challenging operating environment and still deliver a strong set of results for the half. Our community pharmacy brands have again delivered industry leading like-for-like growth of 8.7%, with our upgraded infrastructure easily absorbing a 13% increase in wholesale volumes for the half.”
“Just as pleasing, we are now emerging from a period of significant investment and transformation which has set the business up for the next wave of growth, including the pursuit of acquisition opportunities,” he added.
While management is confident on the medium and long term, it has warned that near term trading conditions remain tough due to COVID-19 restrictions.
As a result, underlying EBITDA is only expected to grow 5% in FY 2022. This is a sharp slowdown on its first half growth and means it is behind on its two-year growth target. That target is for a CAGR of 10% for underlying EBITDA growth in FY 2022 and FY 2023.
Mr Hooper concluded: “We have emerged from the challenges of the last 18 months to deliver a strong first half result and have the business in good shape. However, with the increased impact of COVID-19 restrictions that are expected to stretch well into the 2H22, we are now expecting FY22 Underlying EBITDA growth to be closer to 5%.”
Should you invest $1,000 in Sigma right now?
Before you consider Sigma, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Sigma wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Western Areas (ASX:WSA) share price falls as IGO due diligence begins
Warning to all ETF shareholders doing their tax returns
The Westpac (ASX:WBC) share price has fallen in the last week. Here’s why
CBA (ASX:CBA) share price lower despite latest ‘disruptor’ investment
3 experts pick 3 ASX shares to rocket in next 12 months
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.